



HAL
open science

Reply: Two heterozygous Progranulin mutations in progressive supranuclear palsy

Vincent Huin, Mathieu Barbier, Alexandra Durr, Isabelle Le Ber

► To cite this version:

Vincent Huin, Mathieu Barbier, Alexandra Durr, Isabelle Le Ber. Reply: Two heterozygous Progranulin mutations in progressive supranuclear palsy. *Brain - A Journal of Neurology*, 2021, 10.1093/brain/awaa456. hal-03113276

HAL Id: hal-03113276

<https://hal.sorbonne-universite.fr/hal-03113276>

Submitted on 18 Jan 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Reply: Two heterozygous Progranulin mutations in progressive supranuclear palsy

Madam, Sir,

Thank you for the opportunity to respond to Yang *et al.*, 2020, reporting a patient diagnosed with progressive supranuclear palsy (PSP) who carried two novel heterozygous missense variants in *GRN* gene. The authors report one case, a 65-year-old man who presented with an akinetic-rigid syndrome, postural instability and supranuclear gaze palsy. Clinical signs fulfilled the Movement Disorder Society's clinical diagnostic criteria for probable PSP (Hoglinger *et al.*, 2017). Sequencing of nine genes which pathogenic variants cause dementia (*GRN*, *MAPT*, *C9orf72*, *VCP*, *TARDP*, *CHMP2B*, *APP*, *PSEN1* and *PSEN2*) revealed two heterozygous missense variants, c.745C>G, p.(Gln249Glu) and c.802A>C, p.(Thr268Pro), in the *GRN* gene. The authors suggested that biallelic *GRN* mutations might cause a PSP-like phenotype, allowing further expansion of the phenotypic spectrum of homozygous *GRN* mutations reported by our team (Huin *et al.*, 2020).

Atypical presentations with parkinsonism are known to be less frequent in heterozygous *GRN* mutations carriers than behavioral variant of FTD or primary progressive aphasias. They mainly manifest as a corticobasal syndrome, or a clinical picture resembling dementia with Lewy bodies (Le Ber *et al.*, 2008; Orme *et al.*, 2020; Carneiro *et al.*, 2020). Conversely to *MAPT* mutations or *C9orf72* repeat expansions, pathogenic *GRN* mutations were reported to be a very rare cause of possible PSP (Ogaki *et al.*, 2013). Only a few studies have reported patients with PSP-like phenotypes associated with heterozygous *GRN* null mutations (Rusina *et al.*, 2011; Tremolizzo *et al.*, 2011; Picillo *et al.*, 2020). We previously reported a patient who carried homozygous *GRN* mutations and initially presented, at age 61, with atypical parkinsonism characterized by akinetic-rigid syndrome, unresponsive to L-DOPA treatment, tremor and postural instability, but not fitting criteria for PSP. He rapidly developed frontal cognitive, behavioral and language impairments, within the two first years of the disease, that were consistent with a behavioral variant of FTD (Huin *et al.*, 2020).

The case reported by Yang *et al.*, raises therefore some concerns. It would have been useful to have access to eye movement recordings, a more in-depth cognitive evaluation (in particular, frontal executive functions), and in particular, to details of the clinical progression. Lastly,

information on genetic screening of other genes involved in parkinsonism (particularly *SCNA*, *LRRK2* and *PRKN*) would also have been of interest. The absence of a positive family history, without parental consanguinity, does not provide supportive evidence in favor of variant pathogenicity. Additionally, testing of parents or other first-degree relatives is requested to determine the phase, and for establishing if the two variants are carried by two different alleles, *i.e.* in *trans*, according to the international guidelines for the interpretation of sequence variants (Richards et al., 2015). The study of Yang *et al.*, does not provide clear evidence that the *GRN* variants are in *trans* as no familial segregation analyses were conducted. Without phasing, we cannot exclude that the two variants actually constitute a single pathogenic haplotype, rather than compound heterozygous variants.

Most pathogenic *GRN* mutations are null mutations producing a premature stop codon, leading to the degradation of mutant mRNA and, thereby, to a loss-of-function through haploinsufficiency (Baker *et al.*, 2006; Cruts *et al.*, 2006). PGRN protein, coded by *GRN*, is secreted in bodily fluids, and can be measured in plasma. As a consequence of haploinsufficiency, plasma progranulin level is decreased in *GRN* mutations carriers. Plasma progranulin dosage is thus a simple, reliable and cost-effective marker suitable as a screening tool and to support the causative role of *GRN* mutations with unknown pathogenicity (Güven *et al.*, 2019; Sellami *et al.*, 2020). We and others reported that homozygous *GRN* mutations were associated with an almost complete loss of function of progranulin, accompanied with very low or undetectable plasma progranulin levels (Smith *et al.*, 2012; Canafoglia *et al.*, 2014; Almeida *et al.*, 2016; Faber *et al.*, 2017; Kamate *et al.*, 2019; Huin *et al.*, 2020). Although *in vitro* experiments in the study of Yang *et al.* suggested that the p.(Gln249Glu) and p.(Thr268Pro) variants reduce the stability of progranulin protein, these results would be strongly reinforced *in vivo* by plasma level measurement that, if decreased or undetectable, would provide convincing arguments for variants pathogenicity. This would be of importance, as the majority of *GRN* missense mutations are not, or not proven to be pathogenic, and only rare missense mutations have been associated with reduced gene expression (Shankaran *et al.*, 2008; van der Zee *et al.*, 2007; Saracino *et al.*, 2020) or splice defect (Luzzi *et al.*, 2017), leading to haploinsufficiency as well.

Depending to the interpretation of the level of evidence provided by the *in vitro* experiments, these two missense variants may be classified as "VUS" (Variants of Unknown Significance) according to the American College of Medical Genetics and Genomics guidelines for the interpretation of sequence variants (Richards *et al.*, 2015).

In summary, the study of Yang *et al.*, reports a PSP-like phenotype in a patients carrying two missense variants in *GRN* gene, putatively compound heterozygous. Finally, we suggest that further analyses (including segregation analyses and plasma progranulin dosage) are warranted to draw definite conclusion about the association of these two missense variants with a PSP-like phenotype.

Authors:

Vincent Huin, MD, PhD^{1,2}, Mathieu Barbier, PhD¹, Alexandra Durr, MD, PhD¹, Isabelle Le Ber, MD, PhD^{1,3}

¹ Sorbonne Université, Paris Brain Institute, APHP, INSERM, CNRS, Paris, France

² Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog (JPARC) - Lille Neuroscience & Cognition, F-59000 Lille, France

³ AP-HP, National Reference center "rare and young dementias", IM2A, Pitié-Salpêtrière University Hospital, Paris, France

ORCID number:

Vincent Huin = 0000-0001-8201-5406

Mathieu Barbier = 0000-0002-5154-2163

Alexandra Durr = 0000-0002-8921-7104

Isabelle Le Ber = 0000-0002-2508-5181

Competing interests

The authors report no competing interests.

Funding

This work received funding from the VERUM foundation and ‘Investissements d’avenir’ ANR-11-INBS-0011 – NeurATRIS: Translational Research Infrastructure for Biotherapies in Neurosciences. This work was funded by the Programme Hospitalier de Recherche Clinique (PHRC) FTLD-exome (to I.L.B., promotion by Assistance Publique – Hôpitaux de Paris) and PHRC Predict-progranulin (to I.L.B., promotion by Assistance Publique – Hôpitaux de Paris).

REFERENCES

Almeida MR, Macário MC, Ramos L, Baldeiras I, Ribeiro MH, Santana I. Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. *Neurobiol Aging* 2016; 41: 200.e1-200.e5.

Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* 2006; 442: 916–9.

Canafoglia L, Morbin M, Scaioli V, Pareyson D, D’Incerti L, Fugnanesi V, et al. Recurrent generalized seizures, visual loss, and palinopsia as phenotypic features of neuronal ceroid lipofuscinosis due to progranulin gene mutation. *Epilepsia* 2014; 55: e56-59.

Carneiro F, Saracino D, Huin V, Clot F, Delorme C, Méneret A, et al. Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations. *Parkinsonism & Related Disorders* 2020; 80: 73–81.

Cruts M, Gijssels I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature* 2006; 442: 920–4.

Faber I, Protá JRM, Martínez ARM, Lopes-Cendes I, França MC. A new phenotype associated with homozygous GRN mutations: complicated spastic paraplegia. *Eur J Neurol* 2017; 24: e3–4.

Guven G, Bilgic B, Tufekcioglu Z, Erginel Unaltuna N, Hanagasi H, Gurvit H, et al. Peripheral GRN mRNA and Serum Progranulin Levels as a Potential Indicator for Both the Presence of Splice Site Mutations and Individuals at Risk for Frontotemporal Dementia. *JAD* 2019; 67: 159–67.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria: MDS Clinical Diagnostic Criteria for PSP. *Mov Disord* 2017; 32: 853–64.

Huin V, Barbier M, Bottani A, Lobrinus JA, Clot F, Lamari F, et al. Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms. *Brain* 2020; 143: 303–19.

Kamate M, Detroja M, Hattiholi V. Neuronal ceroid lipofuscinosis type-11 in an adolescent. *Brain and Development* 2019; 41: 542–5.

Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A, et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. *Brain* 2008; 131: 732–46.

Luzzi S, Colleoni L, Corbetta P, Baldinelli S, Fiori C, Girelli F, et al. Missense mutation in GRN gene affecting RNA splicing and plasma progranulin level in a family affected by frontotemporal lobar degeneration. *Neurobiology of Aging* 2017; 54: 214.e1-214.e6.

Ogaki K, Li Y, Takanashi M, Ishikawa K-I, Kobayashi T, Nonaka T, et al. Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTL, PSP, and CBS. *Parkinsonism & Related Disorders* 2013; 19: 15–20.

Orme T, Hernandez D, Ross OA, Kun-Rodrigues C, Darwent L, Shepherd CE, et al. Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. *acta neuropathol commun* 2020; 8: 5.

Picillo M, Vitale E, Rendina A, Donizetti A, Aliperti V, Tepedino MF, et al. Clinical and Molecular Characterization of a Novel Progranulin Deletion Associated with Different Phenotypes. *JAD* 2020; 76: 341–7.

; on behalf of the ACMG Laboratory Quality Assurance Committee, Richards S, Aziz N, Bale S, Bick D, Das S, et al. Standards and guidelines for the interpretation of sequence variants: a

joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015; 17: 405–23.

Rusina R, Kovacs GG, Fiala J, Hort J, Ridzoň P, Holmerová I, et al. FTLD-TDP with motor neuron disease, visuospatial impairment and a progressive supranuclear palsy-like syndrome: broadening the clinical phenotype of TDP-43 proteinopathies. A report of three cases. *BMC Neurol* 2011; 11: 50.

Saracino D, Sellami L, Clot F, Camuzat A, Lamari F, Rucheton B, et al. The missense p.Trp7Arg mutation in GRN gene leads to progranulin haploinsufficiency. *Neurobiology of Aging* 2020; 85: 154.e9-154.e11.

Sellami L, Rucheton B, Ben Younes I, Camuzat A, Saracino D, Rinaldi D, et al. Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. *Neurobiology of Aging* 2020; 91: 167.e1-167.e9.

Shankaran SS, Capell A, Hruscha AT, Fellerer K, Neumann M, Schmid B, et al. Missense Mutations in the Progranulin Gene Linked to Frontotemporal Lobar Degeneration with Ubiquitin-immunoreactive Inclusions Reduce Progranulin Production and Secretion. *J Biol Chem* 2008; 283: 1744–53.

Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. *Am J Hum Genet* 2012; 90: 1102–7.

Tremolizzo L, Bertola F, Casati G, Piperno A, Ferrarese C, Appollonio I. Progressive supranuclear palsy-like phenotype caused by progranulin p.Thr272fs mutation: Letters to the Editors. *Mov Disord* 2011; 26: 1964–6.

van der Zee J, Le Ber I, Maurer-Stroh S, Engelborghs S, Gijssels I, Camuzat A, et al. Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. *Hum Mutat* 2007; 28: 416–416.

Yang W, Deng B, Huang Y, Huang Z, Liu J, Chang Z, et al. Two heterozygous progranulin mutations in progressive supranuclear palsy. *Brain* 2020; *in press*.